Incorporating clinical knowledge and experience in the evaluation of drug development projects using the analytic hierarchy process Online publication date: Fri, 01-Apr-2016
by A. Lawrence Gould; Rajesh Krishna; Anis Khan; Jeffrey Saltzman
International Journal of Business and Systems Research (IJBSR), Vol. 10, No. 2/3/4, 2016
Abstract: Resource limitations require balancing factors such as efficacy, safety, market urgency, etc. to reach objective and consistent decisions at the various stages of drug development. Decisions about pursuing, delaying, or terminating a potential drug depend on the knowledge and experience of the product development team and the findings from completed experiments and trials. We describe how the analytic hierarchy process can be used to inform decisions, and illustrate its application to an actual development project. The dimensions of the decisions, the rankings of the possible outcomes for each dimension, and the rules for combining the components are determined by the key stakeholders before obtaining the determinative data. Laying out the rules before a product reaches a decision point facilitates exploration of the sensitivity of potential decisions to various assumptions. The process can be applied at any stage of clinical development. Its statistical properties can be evaluated using standard statistical decision analysis methods.
Online publication date: Fri, 01-Apr-2016
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business and Systems Research (IJBSR):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org